7 results on '"Mathilde Hunault-Berger"'
Search Results
2. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
- Author
-
Guillermo Ortí, Luuk Gras, Nienke Zinger, Maria Chiara Finazzi, Katja Sockel, Marie Robin, Edouard Forcade, Daniele Avenoso, Nicolaus Kröger, Jürgen Finke, Aleksandar Radujkovic, Mathilde Hunault‐Berger, Wilfried Schroyens, Tsila Zuckerman, Jean Henri Bourhis, Yves Chalandon, Adrian Bloor, Rik Schots, Liesbeth C. de Wreede, Joana Drozd‐Sokolowska, Kavita Raj, Nicola Polverelli, Tomasz Czerw, Juan Carlos Hernández‐Boluda, Donal McLornan, Ibrahim Yakoub‐Agha, Brussels Heritage Lab, Clinical sciences, and Hematology
- Subjects
surgery ,allogeneic hematopoietic cell transplant ,Chronic Malignancies Working Party ,retrospective study ,oncology ,outcome ,blast phase of myeloproliferative neoplasms ,European Society for Blood and Marrow Transplantation ,Human medicine ,Hematology ,transplantation - Abstract
Allogeneic hematopoietic cell transplant (allo-HCT) provides the only potential route to long-term remission in patients diagnosed with blast phase transformation of mye-loproliferative neoplasm (BP-MPN). We report on a large, retrospective European Society for Blood and Marrow Transplantation registry-based study of BP-MPN patients undergoing allo-HCT. BP-MPN patients undergoing first allo-HCT between 2005 and 2019 were included. A total of 663 patients were included. With a median follow-up of 62 months, the estimated 3-year overall survival (OS) was 36% (95% confidence interval [CI], 32-36). Factors associated with lower OS were Karnofsky Performance Score (KPS) < 90 (hazard ratio [HR] 1.65, p < .001) and active disease at allo-HCT (HR 1.45, p < .001), whereas patients undergoing allo-HCT more recently associated with a higher OS (HR 0.96, p = .008). In a selected patient's population, the 3-year OS of patients undergoing allo-HCT in complete response (CR) and with a KPS >= 90 was 60%. KPS < 90 (HR 1.4, p = .001) and active disease (HR 1.44, p = .0004) were associated with a lower progression-free survival (PFS). Conversely, most recent allo-HCT associated with a higher PFS (HR 0.96, p = .008). Active dis-ease at allo-HCT (HR 1.34, p = .03) was associated with a higher cumulative inci-dence of relapse (RI) and allo-HCT in earlier calendar years (HR 0.96, p = .02) associated with a lower RI. Last, KPS < 90 (HR 1.91, p < .001), active disease (HR 1.74, p = .003) and allo-HCT from mismatched related donors were associated with a higher non-relapse mortality (HR 2.66, p = .003). In this large series of BPMPN patients, about one third were alive at 3 years after transplantation. Patients undergoing allo-HCT in the more recent era, with a KPS >= 90 and in CR at transplant had a better prognosis.
- Published
- 2023
3. Outcomes after Allogeneic Hematopoietic Cell Transplant in patients diagnosed with Blast Phase of Myeloproliferative Neoplasms: a retrospective study from the Chronic Malignancies Working Party of the EBMT
- Author
-
Guillermo, Ortí, Luuk, Gras, Nienke, Zinger, Maria Chiara, Finazzi, Katja, Sockel, Marie, Robin, Edouard, Forcade, Daniele, Avenoso, Nicolaus, Kröger, Jürgen, Finke, Aleksandar, Radujkovic, Mathilde, Hunault-Berger, Wilfried, Schroyens, Tsila, Zuckerman, Jean Henri, Bourhis, Yves, Chalandon, Adrian, Bloor, Rik, Schots, Liesbeth C, de Wreede, Joana, Drozd-Sokolowska, Kavita, Raj, Nicola, Polverelli, Tomasz, Czerw, Juan Carlos, Hernández-Boluda, Donal, McLornan, and Ibrahim, Yakoub-Agha
- Abstract
Allogeneic haematopoietic cell transplant (allo-HCT) provides the only potential route to long-term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP-MPN). We report on a large, retrospective EBMT registry-based study of BP-MPN patients undergoing allo-HCT. BP-MPN patients undergoing first allo-HCT between 2005-2019 were included. A total of 663 patients were included. With a median follow-up of 62 months, the estimated 3-year OS was 36% (95% CI, 32-36). Factors associated with lower OS were Karnofsky Performance Status (KPS)90 (HR 1.65, p0.001) and active disease at allo-HCT (HR 1.45, p0.001), whereas patients undergoing allo-HCT more recently associated with a higher OS (HR 0.96, p=0.008). In a selected patients population, the 3-year OS of patients undergoing allo-HCT in complete response (CR) and with a KPS ≥90 was 60%. KPS90 (HR 1.4, p=0.001) and active disease (HR 1.44, p=0.0004) were associated with a lower PFS. Conversely, most recent allo-HCT associated with a higher PFS (HR 0.96, p=0.008). Active disease at allo-HCT (HR 1.34, p=0.03) was associated with a higher cumulative incidence of relapse (RI) and allo-HCT in earlier calendar years (HR 0.96, p=0.02) associated with a lower RI. Lastly, KPS90 (HR 1.91, p0.001), active disease (HR 1.74, p=0.003) and allo-HCT from mismatched related donors were associated with a higher NRM (HR 2.66, p=0.003). In this large series of BP-MPN patients, about one third were alive at 3 years after transplantation. Patients undergoing allo-HCT in the more recent era, with a KPS≥90 and in CR at transplant had a better prognosis. This article is protected by copyright. All rights reserved.
- Published
- 2022
4. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with<scp>l</scp>-asparaginase: The GRAALL experience
- Author
-
Françoise Huguet, Patrice Chevallier, Pierre Bories, Oumedaly Reman, Mathilde Hunault-Berger, Norbert Ifrah, Xavier Thomas, Véronique Lhéritier, Aline Tanguy-Schmidt, Jamile Frayfer, Corentin Orvain, Victoria Cacheux, Etienne Daguindau, Caroline Bonmati, Felipe Suarez, Véronique Dorvaux, Laurence Sanhes, Marie-Anne Couturier, Hervé Dombret, Martine Escoffre-Barbe, and Jean-Michel Pignon
- Subjects
medicine.medical_specialty ,business.industry ,Lymphoblastic lymphoma ,Central nervous system ,Antithrombin ,Induction chemotherapy ,Hematology ,medicine.disease ,Thrombosis ,Gastroenterology ,3. Good health ,Surgery ,Venous thrombosis ,medicine.anatomical_structure ,Internal medicine ,medicine ,Adult Acute Lymphoblastic Leukemia ,business ,Complication ,medicine.drug - Abstract
Central nervous system (CNS) thrombotic events are a well-known complication of acute lymphoblastic leukemia (ALL) induction therapy, especially with treatments including l-asparaginase (l-ASP). Data on risk factors and clinical evolution is still lacking in adult patients. We report on the clinical evolution of 22 CNS venous thrombosis cases occurring in 708 adults treated for ALL or lymphoblastic lymphoma (LL) with the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)-induction protocol, which included eight L-ASP (6,000 IU/m2) infusions. The prevalence of CNS thrombosis was 3.1%. CNS thrombosis occurred after a median of 18 days (range: 11–31) when patients had received a median of three l-ASP injections (range: 2–7). Patients with CNS thrombosis exhibited a median antithrombin (AT) nadir of 47.5% (range: 36–67%) at Day 17 (range: D3–D28), and 95% of them exhibited AT levels lower than 60%. There were no evident increase in hereditary thrombotic risk factors prevalence, and thrombosis occurred despite heparin prophylaxis which was performed in 90% of patients. Acquired AT deficiency was frequently detected in patients with l-ASP-based therapy, and patients with CNS thrombosis received AT prophylaxis (45%) less frequently than patients without CNS thrombosis (83%), P = 0.0002). CNS thrombosis was lethal in 5% of patients, while 20% had persistent sequelae. One patient received all planned l-ASP infusions without recurrence of CNS thrombotic whereas l-ASP injections were discontinued in 20 patients during the management of thrombosis without a significant impact on overall survival (P = 0.4). Am. J. Hematol. 90:986–991, 2015. © 2015 Wiley Periodicals, Inc
- Published
- 2015
5. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study
- Author
-
Martine Escoffre-Barbe, Norbert Ifrah, Françoise Huguet, Ollivier Legrand, Mathilde Hunault-Berger, Chantal Himberlin, Marie C. Béné, Patrice Chevallier, Pierre Bories, Marie Laure Boulland, Caroline Bonmati, Laurence Sanhes, Didier Bouscary, Stéphane Leprêtre, Mario Ojeda-Uribe, Yann Godfrin, Oumedaly Reman, Philippe Rousselot, Hervé Dombret, Severine Lissandre, Pascal Turlure, David Liens, Thibaut Leguay, Eric Deconinck, and Marina Lafage-Pochitaloff
- Subjects
medicine.medical_specialty ,Asparaginase ,business.industry ,Deep vein ,Philadelphia Chromosome Negative ,Phases of clinical research ,Hematology ,Philadelphia chromosome ,medicine.disease ,Gastroenterology ,3. Good health ,Surgery ,chemistry.chemical_compound ,medicine.anatomical_structure ,chemistry ,Internal medicine ,Toxicity ,medicine ,Pancreatitis ,business ,Survival analysis - Abstract
PURPOSE: The GRASPALL/GRAALL-SA2-2008 Phase II trial evaluated the safety and efficacy of L-asparaginase encapsulated within erythrocytes (GRASPA®) in patients ≥ 55 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. FINDINGS: Thirty patients received escalating doses of GRASPA® on Day 3 and 6 of induction Phases 1 and 2. The primary efficacy endpoint was asparagine depletion \textless 2 µmol/L for at least 7 days. This was reached in 85 and 71% of patients with 100 and 150 IU/kg respectively but not with 50 IU/kg. Grade 3/4 infection, hypertransaminasemia, hyperbilirubinemia and deep vein thrombosis occurred in 77, 20, 7, and 7% of patients, respectively. No allergic reaction or clinical pancreatitis was observed despite 17% of Grade 3/4 lipase elevation. Anti-asparaginase antibodies were detected in 50% of patients and related to a reduction in the duration of asparagine depletion during induction Phase 2 without decrease of encapsulated L-asparaginase activity. Complete remission rate was 70%. With a median follow-up of 42 months, median overall survival was 15.8 and 9.7 months, in the 100 and 150 IU/kg cohorts respectively. CONCLUSIONS: The addition of GRASPA®, especially at the 100 IU/kg dose level, is feasible in elderly patients without excessive toxicity and associated with durable asparagine depletion. (clinicaltrials.gov identifier NCT01523782)
- Published
- 2015
6. Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis
- Author
-
Mathilde Hunault-Berger, Aline Renneville, Nicolas Duployez, Martin Figeac, Stéphane Cheze, Christian Rose, Aspasia Stamatoullas-Bastard, Catherine Badens, Thomas Prebet, Virginie Eclache, Anne Murati, Claude Preudhomme, Pierre Fenaux, Sylvie Daliphard, Claude Gardin, Pascale Cony-Makhoul, Blandine Beve, Christian Bastard, Mathieu Decamp, Nicolas Poret, Charles Herbaux, Caroline Lacoste, and Frédéric Maloisel
- Subjects
Oncology ,Mutation rate ,medicine.medical_specialty ,Myeloid ,Point mutation ,Microcytosis ,Myelodysplastic syndromes ,Hematology ,Alpha-thalassemia ,Biology ,medicine.disease ,3. Good health ,medicine.anatomical_structure ,Hemoglobinopathy ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Cancer research ,ATRX - Abstract
Acquired α-thalassemia myelodysplastic syndrome (MDS) (ATMDS) is an acquired syndrome characterized by a somatic point mutation or splicing defect in the ATRX gene in patients with myeloid disorders, primarily MDS. In a large MDS patient series, the incidence of ATMDS was below 0.5%. But no large series has yet assessed the incidence of ATMDS in microcytic MDS. In this study, we focused on patients with MDS and unexplained microcytosis, which was defined as absence of iron deficiency, inflammatory disease, or history of inherited hemoglobinopathy. Our data confirm the low frequency of ATRX mutations in MDS: 0% in an unselected clinical trial cohort of 80 low risk MDS, 0.2-0.8% in a multicenter registry of 2,980 MDS and 43% of MDS with unexplained microcytosis in this same registry. In addition, we reported four novel mutations of the ATRX gene in ATMDS. This study further determines the frequency of ATRX mutations and highlights the importance of microcytosis to detect ATRX mutations within MDS patients.
- Published
- 2015
7. Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis
- Author
-
F. Boyer, L. Macchi, F. Grand, Mathilde Hunault-Berger, J.F. Hamel, and I. Mignon
- Subjects
Adult ,Male ,medicine.medical_specialty ,Gastroenterology ,Thrombin generation ,Lag time ,Endogenous Thrombin Potential ,Reactive thrombocytosis ,Predictive Value of Tests ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Point Mutation ,Thrombophilia ,In patient ,Fluorometry ,Clinical scenario ,Phospholipids ,Aged ,Aged, 80 and over ,Thrombocytosis ,business.industry ,Essential thrombocythemia ,Thrombin ,Hematology ,Janus Kinase 2 ,Middle Aged ,medicine.disease ,ROC Curve ,Area Under Curve ,Immunology ,Colorimetry ,Female ,Blood Coagulation Tests ,business ,Thrombocythemia, Essential - Abstract
Thrombocytosis is a commonly encountered clinical scenario and can be either a secondary process (reactive thrombocytosis), or due to clonal disorder (i.e., essential thrombocythemia). This distinction is important as it carries implications for evaluation, prognosis and treatment. In this study we compared procoagulant potential in essential thrombocythemia and reactive thrombocytosis by measuring the thrombin generation and the level of circulating procoagulant phospholipids with functional tests. Twenty nine patients with essential thrombocythemia and 24 with reactive thrombocytosis were studied. Thrombin generation was determined by calibrated automated thrombography. Procoagulant phospholipids were detected by a chronometric standardised method (STA-Procoag-PPL). Patients with reactive thrombocytosis had a longer lag time, higher endogenous thrombin potential, peak of thrombin generation and velocity index than patients with essential thrombocythemia. The level of circulating procoagulant phospholipids was increased in patients with essential thrombocythemia as observed with the procoagulant phospholipids assay. Each parameter was analysed using ROC curves. Highest areas under the curve (AUC) were found for lag time and procoagulant phospholipids ratio (0.817 and 0.853, respectively), associated with high negative predictive value for ET (92.3% and 80%, respectively). In conclusion, patients with essential thrombocythemia and reactive thrombocytosis displayed significant differences in terms of thrombin generation and levels of procoagulant phospholipids. Among these parameters, lag time and procoagulant phospholipids ratio could help to differentiate between reactive thrombocytosis and essential thrombocythemia patients. Am. J. Hematol. 88:1007–1011, 2013. © 2013 Wiley Periodicals, Inc.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.